(Q35177681)

6 August 2017

1 reference

title

The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review (English)

1 reference

6 August 2017

1 reference

1 reference

Susan D Ross

1

1 reference

6 August 2017

Kyle Fahrbach

2

1 reference

6 August 2017

Diana Frame

3

1 reference

6 August 2017

Rachel Scheye

4

1 reference

6 August 2017

Janet E Connelly

5

1 reference

6 August 2017

John Glaspy

6

1 reference

6 August 2017

publication date

1 June 2003

1 reference

6 August 2017

published in

Clinical Therapeutics

1 reference

6 August 2017

volume

25

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

1786-1805

1 reference

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Systematic reviews: synthesis of best evidence for clinical decisions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Erythropoietin for anaemia in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer--a randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Correction of disease related anaemia of B-chronic lymphoproliferative disorders by recombinant human erythropoietin: maintenance is necessary to sustain response

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Assessment of the quality of life of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Clinical applications of visual analogue scales: a critical review.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Sensitivity and accuracy of the visual analogue scale: a psycho-physical classroom experiment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

The use of analogue scales in rating subjective feelings

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

The development of a subjective health indicator

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Measuring the effectiveness of heart transplant programmes: quality of life data and their relationship to survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

The Sickness Impact Profile: Development and Final Revision of a Health Status Measure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

A disease-specific questionnaire for assessing quality of life in patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Performance status assessment in cancer patients. An inter-observer variability study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Functional status and quality of life: predictors of early mortality among patients entering treatment for end stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Performance status assessment in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Measurement of health status. Ascertaining the minimal clinically important difference

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Interpretation of quality of life changes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

Making sense of quality-of-life data.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980170-4

7 January 2021

10.1016/S0149-2918(03)80170-4

Identifiers

DOI

1 reference

6 August 2017

1 reference